Optimistic Buy Rating for BridgeBio Pharma’s BBP-812: Promising Phase 1/2 Results in Canavan Disease Therapy
Mizuho Securities analyst Salim Syed has maintained their bullish stance on BBIO stock, giving a Buy rating today. Salim Syed’s rating ...
Positive Outlook on BridgeBio Pharma’s BBP-812 Gene Therapy: Buy Rating Reaffirmed
Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on BridgeBio Pharma (BBIO – Research Report), retaining the price target ...
Future Market Insights22h
Insect Cell Lines Market Set to Reach USD 3 Billion by 2033, Growing at a CAGR of 11.6%
Product launches is the main strategy followed by the manufacturers for insect cell lines market. On March 2020, Lonza has ...
Ocuphire Pharma, Inc. Announces Acquisition of Opus Genetics
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate sa ...